ForePass delivers stronger metabolic effects than semaglutide in a short swine model
In a 30-day head-to-head study in young Landrace pigs, ForePass outperformed semaglutide on insulin sensitivity and weight control while also being tested against sham endoscopy. The device is designed to mimic biliopancreatic diversion without an incision, and the metabolic signal emerged quickly enough to raise interest in how much of the benefit came from altered nutrient flow rather than pharmacologic appetite suppression alone.
The study enrolled 12 pigs with a mean body weight of 46.7 ± 1.1 kg and randomized them to ForePass, twice-weekly semaglutide, or sham endoscopy. Sample size was set in advance for the primary endpoint, insulin sensitivity, using an expected difference of 0.6 min−1·pM−1, an SD of 0.3, α of 0.05, and 80% power, which yielded four animals per group. That design is small by human clinical standards, but it is appropriately structured for a controlled mechanistic animal experiment focused on metabolic physiology rather than long-term outcomes.
The primary readout favored ForePass decisively. Insulin sensitivity reached 2.75 ± 0.37 min−1·pM−1 with ForePass, compared with 1.34 ± 0.21 min−1·pM−1 with semaglutide and 0.78 ± 0.46 in the sham group. The difference is biologically important because insulin sensitivity sits near the center of glucose homeostasis: when peripheral tissues respond better to insulin, less compensatory secretion is needed, hepatic glucose output is more tightly controlled, and postprandial handling becomes more efficient. In a model built to approximate biliopancreatic diversion, that pattern is consistent with a surgical physiology effect produced through an endoscopic route.
The study also followed body weight, oral glucose tolerance, endogenous glucose production, disposition index, oral glucose rate of appearance, plasma metabolomics, and fecal microbiota. Those secondary domains matter because they can separate a pure appetite effect from a broader rearrangement of nutrient sensing, bile acid signaling, gut hormone release, and microbial ecology. Semaglutide, a GLP-1 receptor agonist, has a well-established metabolic profile, but the device approach was engineered to alter the intestinal passage of nutrients and may therefore act upstream of several pathways at once.
One sentence captures the biological tension here: a device that reroutes the gut can change glucose metabolism without relying on receptor agonism alone.
That matters because the gut is not just a conduit for absorption. It is an endocrine and microbial organ, and procedures that shift nutrient exposure in the proximal intestine can alter incretin biology, hepatic glucose production, bile acid circulation, and downstream microbial composition. ForePass was built to mimic biliopancreatic diversion, a mechanism that has long been associated with large metabolic gains after bariatric procedures. By reproducing some of that anatomy endoscopically and reversibly, the intervention attempts to harvest surgical metabolic effects while avoiding an incision.
The comparison with semaglutide is especially relevant because weight-loss pharmacotherapy has become a dominant treatment paradigm, yet pharmacology and anatomy do not behave identically. Semaglutide reduces appetite and delays gastric emptying, which can be powerful, but it does not recreate the intestinal rerouting that follows bariatric diversion. If ForePass truly delivers stronger insulin sensitivity in a short time frame, the result suggests that the spatial organization of nutrient exposure may still be a major determinant of metabolic benefit, not merely a detail of procedure design.
The abstract also points to analyses of endogenous glucose production, disposition index, plasma metabolomics, and fecal microbiota, implying that the investigators were looking for a systems-level signature rather than a single isolated effect. In practical metabolic terms, that is the right question. Insulin sensitivity can improve because hepatic glucose output falls, because peripheral disposal improves, because insulin secretion becomes more efficient, or because all three occur together. Metabolomics and microbiota profiling may help explain whether the intervention shifts substrate flux, bile acid pathways, or microbial communities in ways that reinforce the glucose-lowering phenotype.
ForePass therefore sits at the intersection of endoscopy, metabolic surgery, and obesity medicine. The platform is reversible and incision-free, which may matter to patients and clinicians who want a procedure-based option without permanent anatomic reconstruction. Yet the current evidence described here comes from a small, short-duration swine study. Young healthy pigs are useful for controlled physiology, but they are not humans with obesity, diabetes, fatty liver disease, or decades of metabolic adaptation. Translation will depend on whether the same signal holds over longer follow-up, in diseased animals or people, and with careful evaluation of nutritional tolerance, safety, durability, and device-related complications.
The data stop at proof-of-concept rather than practice change. What they do show is a clear hierarchy in a tightly controlled model: ForePass produced stronger insulin-sensitizing effects than semaglutide over 30 days, with the experiment also set up to probe why the difference emerged through glucose flux, metabolomics, and microbiota analysis. Until human data arrive, the main clinical question is not whether the signal exists, but whether an endoscopically delivered diversion can sustain it outside the barn and into real metabolic disease.